Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams

What It Covers

Dr. Nolan Williams, Stanford neurologist-psychiatrist, explains how transcranial magnetic stimulation and psychedelics like psilocybin, MDMA, and ibogaine rewire depression and PTSD circuits. Both approaches target the same subgenual anterior cingulate-default mode network connection, producing remission in days without drugs remaining in the system.

Key Questions Answered

• •Stanford Neuromodulation Therapy (SNT): By applying TMS every hour for ten hours across five consecutive days, Williams' protocol delivers the equivalent of seven and a half months of standard TMS treatment. This spaced-learning approach produces full mood remission in 60–90% of patients within one to five days, with some maintaining remission for four or more years.
• •MDMA for PTSD: In clinical trials using 75–150mg MDMA administered one to two times under physician supervision, approximately two-thirds of PTSD patients achieved clinically significant symptom reduction. Effects lasted years in follow-up studies, compared to ketamine infusions, which average only ten days of relief per session before repeat dosing is required.
• •Psilocybin for Depression: Open-label psilocybin trials show 50–67% of patients achieving remission from depression; blinded controlled trials show roughly one-third responding. Both psilocybin and SNT produce the same measurable brain change: reduced connectivity between the negatively valenced subgenual anterior cingulate and the default mode network, suggesting a shared therapeutic mechanism.
• •Circuit Model Replaces Chemical Imbalance: Depression is not a serotonin deficit but a dysregulated prefrontal-cingulate circuit where the left dorsolateral prefrontal cortex fails to govern the conflict-detection system. TMS works by exogenously restoring that top-down regulation without altering serotonin, reframing depression as a correctable electrophysiological arrhythmia rather than a permanent chemical or psychological deficit.
• •Ibogaine for Moral Injury and PTSD: Ibogaine, extracted from African iboga root bark, produces a 24–36 hour closed-eye life-review experience that special operations veterans describe as enabling self-forgiveness for combat-related moral injury. Williams' ongoing first-in-human neurobiological study measures pre- and post-treatment depression scales, PTSD scales, neurocognitive batteries, neuroimaging, and EEG to quantify these effects systematically.